Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812 [PMID: 27076765 DOI: 10.3748/wjg.v22.i14.3803]
Corresponding Author of This Article
Seong Hoon Kim, MD, PhD, Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, South Korea. kshlj@ncc.re.kr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812 [PMID: 27076765 DOI: 10.3748/wjg.v22.i14.3803]
World J Gastroenterol. Apr 14, 2016; 22(14): 3803-3812 Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation
Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park
Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea
Author contributions: Lee EC, Kim SH, Lee SD, Park H, Lee SA and Park SJ designed the research; Lee EC, Lee SD, Park H performed the research and analyzed the data; Lee EC wrote the paper; Kim SH supervised the study and revised the paper.
Institutional review board statement: This study was approved by the Institutional Review Board of National Cancer Center, Republic of Korea.
Informed consent statement: We obtained a waiver of informed consent with the Institutional Review Board of our center.
Conflict-of-interest statement: No conflicts of interest were declared for all authors.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at kshlj@ncc.re.kr. No additional data are available.
Correspondence to: Seong Hoon Kim, MD, PhD, Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, South Korea. kshlj@ncc.re.kr
Telephone: +82-31-9201647 Fax: +82-31-9201138
Received: November 9, 2015 Peer-review started: November 10, 2015 First decision: November 27, 2015 Revised: December 13, 2015 Accepted: January 9, 2016 Article in press: January 11, 2016 Published online: April 14, 2016 Processing time: 140 Days and 17.7 Hours
Core Tip
Core tip: This is a single center analysis of the effects of high-dose hepatitis B immunoglobulin (HBIG) therapy on the recurrence of hepatocellular carcinoma and hepatitis B in hepatitis B virus (HBV)-DNA/hepatitis B e antigen (HBeAg)-positive patients after LDLT. High-dose HBIG therapy can be helpful in improving hepatocellular carcinoma recurrence-free survival in HBV-DNA/HBeAg-positive recipients who met the Milan criteria. In contrast, high-dose HBIG therapy was not effective in improving HCC recurrence-free survival in HBV-DNA/HBeAg-positive recipients who did not meet the Milan criteria. Recurrence of hepatitis B and overall survival were not affected by the HBIG dose in HBV-DNA/HBeAg-positive recipients regardless of the Milan status.
